New therapeutic options can make a difference for diabetic patients with high CV risk
Video navigation menu
- Interaction between diabetes & cardiovascular practice important for patient care 00:27
- Introduction of 2 new drug classes with CV benefits for diabetic patients 01:35
- New way of treating patients with diabetes and CVD 02:53
Persons with type 2 diabetes are at an elevated risk for cardiovascular disease. Results of several recent CV outcome trials indicate that two classes of drugs may have CV benefits in T2DM. This recording aims to highlight the practical implications of these trials.
Prof. John E Deanfield, MD is Professor of Cardiology, Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: